{"id":3885,"date":"2017-08-12T18:58:11","date_gmt":"2017-08-12T18:58:11","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/deep-local-hyperthermia-meht\/"},"modified":"2026-02-12T09:28:51","modified_gmt":"2026-02-12T09:28:51","slug":"hipertermia-rf-modulada","status":"publish","type":"page","link":"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-rf-modulada\/","title":{"rendered":"Hipertermia RF Modulada ( RF mHT 13,56 MHz + RF espec\u00edfica para patologia )"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"Article\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-rf-modulada\/#article\",\n      \"mainEntityOfPage\": {\n        \"@type\": \"WebPage\",\n        \"@id\": \"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-rf-modulada\/\"\n      },\n      \"headline\": \"Hipertermia RF Modulada - 13.56 MHz mHT\",\n      \"description\": \"A hipertermia por RF modulada (mHT) \u00e9 uma terapia t\u00e9rmica de vanguarda que visa e destr\u00f3i seletivamente c\u00e9lulas malignas sem danificar tecidos saud\u00e1veis. Esta inova\u00e7\u00e3o m\u00e9dica de \u00faltima gera\u00e7\u00e3o fornece energia profunda, precisa e controlada (combinando efeitos hipert\u00e9rmicos e eletromagn\u00e9ticos) usando radiofrequ\u00eancia de 13.56 MHz modulada em amplitude e acoplada capacitivamente \u00e0s c\u00e9lulas cancer\u00edgenas, aumentando a efic\u00e1cia da quimioterapia, radioterapia e imunoterapia, e melhorando os resultados dos pacientes e a sua qualidade de vida.\",\n      \"image\": {\n        \"@type\": \"ImageObject\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/07\/modulated-RF-HT-selective-cancer-cells-300x213.jpg\",\n        \"width\": 300,\n        \"height\": 213,\n        \"caption\": \"Hipertermia por RF modulada - seletividade em c\u00e9lulas cancer\u00edgenas\"\n      },\n      \"datePublished\": \"2025-07-28T00:00:00+02:00\",\n      \"dateModified\": \"2026-02-12T00:00:00+02:00\",\n      \"author\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"keywords\": [\n        \"Hipertermia RF modulada\", \"mHT\", \"13.56 MHz\", \"tratamento oncol\u00f3gico seletivo\",\n        \"efeitos hipert\u00e9rmicos\", \"efeitos eletromagn\u00e9ticos\", \"terapia do cancro\",\n        \"potencia\u00e7\u00e3o da quimioterapia\", \"potencia\u00e7\u00e3o da radioterapia\", \"potencia\u00e7\u00e3o da imunoterapia\",\n        \"efeito abscopal\", \"sobreviv\u00eancia global\", \"qualidade de vida\", \"terapia adjuvante\",\n        \"terapia neoadjuvante\", \"terapia paliativa\", \"infe\u00e7\u00f5es\", \"inflama\u00e7\u00e3o\", \"dor\",\n        \"Andromedic HyDeep 600WM\", \"modula\u00e7\u00e3o RF\", \"microambiente tumoral\", \"DAMP\", \"ICD\",\n        \"morte celular imunog\u00e9nica\", \"HSPs\", \"c\u00e9lulas NK\", \"c\u00e9lulas DC\", \"CTL\", \"Th1\", \"Tmemory\",\n        \"nivolumab\", \"ipilimumab\", \"interleucina 2\"\n      ],\n      \"about\": [\n        {\n          \"@type\": \"MedicalTherapy\",\n          \"name\": \"Hipertermia RF Modulada\",\n          \"alternateName\": [\"mHT\", \"hipertermia por radiofrequ\u00eancia\", \"terapia de hipertermia\"]\n        },\n        {\n          \"@type\": \"MedicalCondition\",\n          \"name\": \"Cancro\",\n          \"alternateName\": [\"C\u00e9lulas malignas\", \"Tumores\", \"Patologias oncol\u00f3gicas\", \"Patologias neopl\u00e1sicas\"]\n        },\n        {\n          \"@type\": \"MedicalDevice\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/pt-pt\/dispositivo-de-hipertermia-onco\/#device\",\n          \"name\": \"Dispositivo mHT HyDeep 600WM da Andromedic\",\n          \"description\": \"O HyDeep 600 WM \u00e9 um sistema\/dispositivo de hipertermia oncol\u00f3gica avan\u00e7ada, sistema\/dispositivo de hipertermia local profunda, sistema\/dispositivo de hipertermia RF modulada e sistema\/dispositivo de eletro-hipertermia.\",\n          \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n          \"url\": \"https:\/\/andromedichyperthermia.com\/pt-pt\/dispositivo-de-hipertermia-onco\/\"\n        },\n        {\n          \"@type\": \"MedicalTherapy\",\n          \"name\": \"Quimioterapia\",\n          \"url\": \"https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294\"\n        },\n        {\n          \"@type\": \"MedicalTherapy\",\n          \"name\": \"Radioterapia\",\n          \"url\": \"https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294\"\n        },\n        {\n          \"@type\": \"MedicalTherapy\",\n          \"name\": \"Imunoterapia\",\n          \"url\": \"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4569\"\n        }\n      ],\n      \"mentions\": [\n        { \"@type\": \"Thing\", \"name\": \"13.56 MHz\", \"description\": \"Frequ\u00eancia portadora de radiofrequ\u00eancia\" },\n        { \"@type\": \"Thing\", \"name\": \"Modula\u00e7\u00e3o RF\" },\n        { \"@type\": \"Thing\", \"name\": \"Efeitos eletromagn\u00e9ticos\" },\n        { \"@type\": \"Thing\", \"name\": \"Efeitos t\u00e9rmicos\" },\n        { \"@type\": \"Thing\", \"name\": \"Acoplamento capacitivo\" },\n        { \"@type\": \"Thing\", \"name\": \"Imped\u00e2ncia\" },\n        { \"@type\": \"Thing\", \"name\": \"Eletr\u00f3lito extracelular\" },\n        { \"@type\": \"Thing\", \"name\": \"Mecanismo de repara\u00e7\u00e3o de ADN\" },\n        { \"@type\": \"Thing\", \"name\": \"Perfus\u00e3o\" },\n        { \"@type\": \"Thing\", \"name\": \"Oxigena\u00e7\u00e3o\" },\n        { \"@type\": \"Thing\", \"name\": \"Efeito de vasodilata\u00e7\u00e3o\" },\n        { \"@type\": \"Thing\", \"name\": \"Radiosensibiliza\u00e7\u00e3o\" },\n        { \"@type\": \"Thing\", \"name\": \"Microambiente Tumoral\", \"alternateName\": \"TME\" },\n        { \"@type\": \"Thing\", \"name\": \"DAMP\", \"description\": \"Padr\u00f5es Moleculares Associados ao Perigo\" },\n        { \"@type\": \"Thing\", \"name\": \"Morte Celular Imunog\u00e9nica\", \"alternateName\": \"ICD\" },\n        { \"@type\": \"Thing\", \"name\": \"Prote\u00ednas de Choque T\u00e9rmico\", \"alternateName\": \"HSPs\" },\n        { \"@type\": \"Thing\", \"name\": \"C\u00e9lulas Exterminadoras Naturais\", \"alternateName\": \"NK cells\" },\n        { \"@type\": \"Thing\", \"name\": \"C\u00e9lulas dendr\u00edticas\", \"alternateName\": \"DC cells\" },\n        { \"@type\": \"Thing\", \"name\": \"Linf\u00f3citos T citot\u00f3xicos\", \"alternateName\": \"CTL\" },\n        { \"@type\": \"Thing\", \"name\": \"C\u00e9lulas T auxiliares\", \"alternateName\": \"Th1\" },\n        { \"@type\": \"Thing\", \"name\": \"C\u00e9lulas T de mem\u00f3ria\", \"alternateName\": \"Tmemory\" },\n        { \"@type\": \"Thing\", \"name\": \"Efeito abscopal\" },\n        { \"@type\": \"Thing\", \"name\": \"Sobreviv\u00eancia Global\", \"alternateName\": \"OS\" },\n        { \"@type\": \"Thing\", \"name\": \"Qualidade de Vida\", \"alternateName\": \"QoL\" },\n        { \"@type\": \"Thing\", \"name\": \"Terapia adjuvante\" },\n        { \"@type\": \"Thing\", \"name\": \"Terapia neoadjuvante\" },\n        { \"@type\": \"Thing\", \"name\": \"Terapia paliativa\" },\n        { \"@type\": \"Person\", \"name\": \"Hegyi G\" },\n        { \"@type\": \"Person\", \"name\": \"Szasz O\" },\n        { \"@type\": \"Person\", \"name\": \"Szasz A\" },\n        { \"@type\": \"Person\", \"name\": \"Ralph Kleef\" },\n        { \"@type\": \"Thing\", \"name\": \"Nivolumab\" },\n        { \"@type\": \"Thing\", \"name\": \"Ipilimumab\" },\n        { \"@type\": \"Thing\", \"name\": \"Interleucina 2\" }\n      ],\n      \"citation\": [\n        \"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5356646\/\",\n        \"https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294#f1-kmj-24-127\",\n        \"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4569\",\n        \"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9939221\/\",\n        \"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10663566\/\"\n      ]\n    },\n    {\n      \"@type\": \"MedicalOrganization\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\",\n      \"name\": \"Andromedic Hyperthermia\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/pt-pt\/\",\n      \"logo\": {\n        \"@type\": \"ImageObject\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/logo.png\"\n      }\n    }\n  ]\n}\n<\/script><\/p>\n<div class=\"mht-clinical-container\" style=\"max-width: 1100px; margin: 0 auto; font-family: 'Segoe UI', Roboto, Helvetica, Arial, sans-serif; color: #2c3e50; line-height: 1.7;\">\n<header style=\"border-bottom: 3px solid #004a99; margin-bottom: 30px; padding-bottom: 20px;\">\n<h1 style=\"color: #004a99; font-size: 2.4em; margin-bottom: 10px;\">Hipertermia RF Modulada &#8211; Tecnologia mHT de 13.56 MHz<\/h1>\n<p style=\"font-size: 1.15em; font-weight: 400;\">A hipertermia RF modulada (mHT) \u00e9 uma terapia de aquecimento avan\u00e7ada que utiliza <strong>efeitos t\u00e9rmicos e n\u00e3o t\u00e9rmicos (eletromagn\u00e9ticos) sin\u00e9rgicos<\/strong> para aquecer e destruir c\u00e9lulas malignas de forma <strong>SELETIVA<\/strong>, sem danificar as c\u00e9lulas saud\u00e1veis.<\/p>\n<\/header>\n<div style=\"display: flex; flex-wrap: wrap; gap: 40px; margin-bottom: 50px; align-items: flex-start;\">\n<div style=\"flex: 1; min-width: 320px;\">\n<p>A mHT \u00e9 a inova\u00e7\u00e3o m\u00e9dica de \u00faltima gera\u00e7\u00e3o que fornece <strong>energia seletiva, controlada e profunda (hipertermia + eletromagnetismo)<\/strong> \u00e0s c\u00e9lulas cancer\u00edgenas, utilizando radiofrequ\u00eancia de 13.56 MHz com modula\u00e7\u00e3o de amplitude acoplada capacitivamente.<\/p>\n<div style=\"background: #f0f7ff; border-left: 5px solid #004a99; padding: 20px; margin: 20px 0;\">\n<h2 style=\"margin-top: 0; color: #004a99; font-size: 1.3em;\">A\u00e7\u00e3o Profunda Superior em Oncologia<\/h2>\n<p>O sistema mHT de 13.56 MHz com 2 el\u00e9trodos pode penetrar at\u00e9 <strong>38.4 cm de profundidade<\/strong> e demonstrou ser superior \u00e0 cCHT de 8 MHz<br \/>\n<a style=\"color: #004a99; text-decoration: underline;\" title=\"Estudo comparativo sobre hipertermia 13.56 MHz vs 8 MHz\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5356646\/\" target=\"_blank\" rel=\"noopener\">(Refer\u00eancia)<\/a>.<\/p>\n<\/div>\n<p>A mHT fornece energia t\u00e9rmica apenas \u00e0 membrana da c\u00e9lula tumoral e \u00e0 matriz extracelular, utilizando temperaturas abaixo de 43 \u00b0C, superando as limita\u00e7\u00f5es da hipertermia tradicional a um <strong>n\u00edvel quase celular<\/strong>.<\/p>\n<\/div>\n<div style=\"flex: 1; min-width: 320px; text-align: center;\">\n<figure style=\"margin: 0; background: #fff; padding: 15px; border: 1px solid #e1e8ed; border-radius: 8px; box-shadow: 0 4px 12px rgba(0,0,0,0.08);\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone\" style=\"width: 100%; height: auto; border-radius: 4px;\" title=\"Mecanismo seletivo da mHT\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/07\/modulated-RF-HT-selective-cancer-cells-300x213.jpg\" alt=\"Mecanismo de alvo seletivo da hipertermia RF modulada mHT em c\u00e9lulas cancer\u00edgenas - Mecanismo de alvo seletivo da hipertermia RF modulada HyDeep 600WM\" width=\"300\" height=\"213\" \/><figcaption style=\"font-size: 0.9em; text-align: left; padding-top: 15px; line-height: 1.4; color: #576574;\"><strong>Fig. 1. Mecanismo seletivo da mHT.<\/strong> A corrente de radiofrequ\u00eancia modulada flui principalmente para o eletr\u00f3lito extracelular, uma vez que as c\u00e9lulas normais est\u00e3o eletronicamente isoladas por uma for\u00e7a de campo el\u00e9trico superior a um milh\u00e3o de V\/m <em>(Hegyi G, Szasz O, Szasz A. PMID: 24494322.)<\/em><\/figcaption><\/figure>\n<\/div>\n<\/div>\n<h2 style=\"color: #004a99; text-align: center; margin-bottom: 35px;\">Os Benef\u00edcios Cl\u00ednicos da Hipertermia RF com Modula\u00e7\u00e3o de Amplitude<\/h2>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit, minmax(320px, 1fr)); gap: 25px; margin-bottom: 50px;\">\n<div style=\"background: #fff; border: 1px solid #e1e8ed; border-top: 4px solid #004a99; padding: 25px; border-radius: 0 0 8px 8px;\">\n<h3 style=\"margin-top: 0; color: #004a99; font-size: 1.2em;\">Quimioterapia e Suporte Biol\u00f3gico<\/h3>\n<p style=\"font-size: 0.95em;\"><strong>Melhor perfus\u00e3o:<\/strong> Devido ao efeito de vasodilata\u00e7\u00e3o, a mHT garante uma melhor entrega de subst\u00e2ncias quimioter\u00e1picas ou biol\u00f3gicas <a title=\"Kosin Medical Journal: Resultados da hipertermia\" href=\"https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294\" target=\"_blank\" rel=\"noopener\">(ref)<\/a>, melhorando os resultados do tratamento.<\/p>\n<\/div>\n<div style=\"background: #fff; border: 1px solid #e1e8ed; border-top: 4px solid #004a99; padding: 25px; border-radius: 0 0 8px 8px;\">\n<h3 style=\"margin-top: 0; color: #004a99; font-size: 1.2em;\">Radiossensibiliza\u00e7\u00e3o<\/h3>\n<p style=\"font-size: 0.95em;\">As altera\u00e7\u00f5es na <strong>oxigena\u00e7\u00e3o<\/strong> do tumor e tecidos adjacentes tornam a mHT uma excelente escolha antes e depois da radioterapia, sensibilizando o tumor para uma efic\u00e1cia radioter\u00e1pica refor\u00e7ada <a title=\"Estudo sobre radiossensibiliza\u00e7\u00e3o e mHT\" href=\"https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294\" target=\"_blank\" rel=\"noopener\">(ref)<\/a>.<\/p>\n<\/div>\n<div style=\"background: #fdf2f2; border: 1px solid #f8d7da; border-top: 4px solid #d9534f; padding: 25px; border-radius: 0 0 8px 8px;\">\n<h3 style=\"margin-top: 0; color: #c0392b; font-size: 1.2em;\">Efeitos Imunog\u00e9nicos (Abscopal)<\/h3>\n<p style=\"font-size: 0.9em; line-height: 1.5;\"><strong>Indutor de ICD:<\/strong> A mHT modula o Microambiente Tumoral (TME), ativando <strong>DAMP<\/strong> e <strong>HSP70<\/strong>. Isto ativa as c\u00e9lulas NK e matura as C\u00e9lulas Dendr\u00edticas (DC), criando uma resposta sist\u00e9mica em met\u00e1stases distantes.<\/p>\n<div style=\"font-family: monospace; font-size: 0.85em; background: #fff; padding: 10px; border-radius: 4px; border: 1px dashed #d9534f; margin-top: 10px;\">mHT (indutor ICD) -&gt; DAMP -&gt; HSP70 -&gt; DC -&gt; C\u00e9lulas T (CTL, Th1, Tmemory) -&gt; <strong>Resposta Antitumoral Sist\u00e9mica<\/strong><\/div>\n<p style=\"font-size: 0.85em; margin-top: 10px; color: #7f8c8d;\">Demonstrou superioridade face ao nivolumab e ipilimumab em cancros gastrointestinais por Ralph Kleef et. al<br \/>\n<a title=\"Estudo de Ralph Kleef sobre mHT e Imunoterapia\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10663566\/\" target=\"_blank\" rel=\"noopener\">(ref)<\/a>.<\/p>\n<\/div>\n<\/div>\n<div style=\"background: #f8fbff; padding: 30px; border-radius: 12px; border: 1px solid #e1e8ed; margin-bottom: 50px;\">\n<h3 style=\"color: #004a99; margin-top: 0;\">Resultados Cl\u00ednicos: Sobreviv\u00eancia Global (OS) e QoL<\/h3>\n<p>O <strong>aumento da Sobreviv\u00eancia Global (OS)<\/strong> no cancro foi demonstrado clinicamente m\u00faltiplas vezes com a adi\u00e7\u00e3o de mHT, al\u00e9m do controlo tumoral local e do aumento da <strong>Qualidade de Vida (QoL)<\/strong> <a title=\"Evid\u00eancia cl\u00ednica sobre OS e QoL com mHT\" href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4569\" target=\"_blank\" rel=\"noopener\">(ref)<\/a>.<\/p>\n<p style=\"font-style: italic; font-size: 0.95em; color: #576574;\">Suporta terapia adjuvante, neoadjuvante e paliativa para patologias neopl\u00e1sicas, infe\u00e7\u00f5es, inflama\u00e7\u00e3o e gest\u00e3o da dor.<\/p>\n<\/div>\n<section style=\"background: linear-gradient(135deg, #004a99 0%, #002d5d 100%); color: #fff; padding: 40px; border-radius: 15px; text-align: center; box-shadow: 0 10px 20px rgba(0,74,153,0.2);\">\n<h2 style=\"color: #fff; margin-top: 0; font-size: 1.8em;\">mHT Avan\u00e7ada: Andromedic HyDeep 600WM<\/h2>\n<p style=\"font-size: 1.1em; max-width: 800px; margin: 0 auto 25px auto;\">O <strong>dispositivo de hipertermia oncol\u00f3gica avan\u00e7ada<\/strong> da Andromedic utiliza 13.56 MHz como RF portadora e combina-a com <strong>Radiofrequ\u00eancias Espec\u00edficas para Cada Patologia e Tipo de Cancro<\/strong>, melhorando significativamente os resultados da mHT cl\u00e1ssica.<\/p>\n<p><a style=\"display: inline-block; background: #ffd700; color: #002d5d; padding: 15px 35px; border-radius: 30px; text-decoration: none; font-weight: bold; font-size: 1.1em; transition: transform 0.2s;\" href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/dispositivo-de-hipertermia-onco\/\"><br \/>\nExplorar a Tecnologia do Dispositivo HyDeep 600WM<br \/>\n<\/a><\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A hipertermia RF modulada (mHT) \u00e9 uma terapia de aquecimento que utiliza efeitos t\u00e9rmicos e n\u00e3o t\u00e9rmicos (eletromagn\u00e9ticos) sin\u00e9rgicos para aquecer e destruir c\u00e9lulas malignas de forma SELETIVA, sem danificar as c\u00e9lulas saud\u00e1veis. A mHT representa a inova\u00e7\u00e3o m\u00e9dica de \u00faltima gera\u00e7\u00e3o, fornecendo energia seletiva, controlada e profunda (hipert\u00e9rmica + eletromagn\u00e9tica) atrav\u00e9s de radiofrequ\u00eancia de 13,56 MHz com modula\u00e7\u00e3o de amplitude, acoplada capacitivamente, direcionada \u00e0s c\u00e9lulas cancer\u00edgenas.<\/p>\n<p>A mHT de 13,56 MHz, utilizando dois el\u00e9trodos, possui a capacidade de penetrar at\u00e9 38,4 cm de profundidade, tendo demonstrado superioridade face \u00e0 cCHT de 8 MHz.<\/p>\n<p>Adicionalmente, o HyDeep 600WM (um dispositivo de hipertermia oncol\u00f3gica avan\u00e7ada \/ sistema de hipertermia local profunda) utiliza os 13,56 MHz como radiofrequ\u00eancia (RF) portadora e combina-a com Radiofrequ\u00eancias Espec\u00edficas para Cada Patologia e Tipo de Cancro. Esta abordagem inovadora tem o potencial de otimizar significativamente os resultados cl\u00ednicos em compara\u00e7\u00e3o com a mHT de 13,56 MHz convencional.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3885","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/pages\/3885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=3885"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/pages\/3885\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=3885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}